Research and Development (R&D) expenses: R&D expenses were $13.7 million for the three months ended December 31, 2025, compared to $6.0 million for the comparable period in 2024, and were $46.7 ...
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business up ...
Neil Varma reinforces that the ability to decline projects, defer initiatives, or consolidate overlapping programs signals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results